標題: Titlebook: Urologic Oncology; Multidisciplinary Ca Kelly L. Stratton,Alicia K. Morgans Book 2022 The Editor(s) (if applicable) and The Author(s), unde [打印本頁] 作者: dabble 時間: 2025-3-21 16:33
書目名稱Urologic Oncology影響因子(影響力)
書目名稱Urologic Oncology影響因子(影響力)學科排名
書目名稱Urologic Oncology網(wǎng)絡公開度
書目名稱Urologic Oncology網(wǎng)絡公開度學科排名
書目名稱Urologic Oncology被引頻次
書目名稱Urologic Oncology被引頻次學科排名
書目名稱Urologic Oncology年度引用
書目名稱Urologic Oncology年度引用學科排名
書目名稱Urologic Oncology讀者反饋
書目名稱Urologic Oncology讀者反饋學科排名
作者: FRONT 時間: 2025-3-21 23:18
Creating a Multidisciplinary Clinic,Multidisciplinary clinics (MDCs) have emerged as a strategy to simplify the process for patients and provide a forum for clinicians of different disciplines to evaluate and discuss patient care in real time. This has led to improved patient satisfaction and outcomes. There is no universal definition作者: 想象 時間: 2025-3-22 02:06 作者: ellagic-acid 時間: 2025-3-22 05:23 作者: 散布 時間: 2025-3-22 11:32
High-Risk Localized Prostate Cancer,calized curable tumors to men with occult metastatic potentially incurable tumors. Therefore, risk stratification, judicious use of imaging, and integration of multimodality therapy are necessary to achieve optimal survival. Clinicians must have familiarity with the full spectrum of management strat作者: 懶鬼才會衰弱 時間: 2025-3-22 13:58
Treatment of Metastatic Hormone-Sensitive Prostate Cancer,d ability to detect men with metastatic disease still in the hormone-sensitive space has altered the standard of care for advanced prostate cancer..: To describe the biologic basis, evidence, and rationale for use of available treatments for men with metastatic hormone-sensitive prostate cancer (mHS作者: GOUGE 時間: 2025-3-22 17:29
Expanding Options for M0 Castration-Resistant Prostate Cancer (CRPC),tinuously exposed to castration levels of androgen deprivation therapy (ADT), but in whom no radiographic evidence of metastatic disease can be identified. Prior to 2018, observation with or without the initiation of first-generation anti-androgen therapy or clinical trial enrollment was the guideli作者: 細菌等 時間: 2025-3-23 00:33 作者: Optic-Disk 時間: 2025-3-23 02:08
Advances in Prostate Cancer Imaging,es, in part, the purpose of staging and risk-stratifying patients to formulate the most effective treatment plan with the least adverse side effects. However, traditional imaging techniques could only serve this role with significant limitations. Computed tomography (CT), for instance, has a size cr作者: 低位的人或事 時間: 2025-3-23 06:59 作者: Vulnerable 時間: 2025-3-23 13:33
Radiotherapy for Advanced Prostate Cancer,ic grading systems [1]. Prostate cancer is no exception, and accurate risk stratification is paramount to appropriately guide therapy for men with prostate cancer. Traditionally, the treatment of localized or non-metastatic malignancies includes radical local therapy with either radiotherapy or surg作者: Irritate 時間: 2025-3-23 15:32
Optimizing Perioperative Treatment for Kidney Cancer,icians can risk-stratify surgical candidates, make recommendations on targeting vulnerabilities and deficits identified in preoperative assessment, and summarize best practices regarding surgical considerations, postoperative care, and follow-up. In this chapter, we review traditional and commonly u作者: Antarctic 時間: 2025-3-23 21:05
Surgical Treatment for Metastatic Kidney Cancer,atic renal cell carcinoma. The role of cytoreductive nephrectomy and metastasectomy for patients with metastatic disease has evolved accordingly. Historically, level 1 evidence supported the use of cytoreductive nephrectomy in patients treated with interferon. While retrospective studies suggest cyt作者: 聯(lián)合 時間: 2025-3-23 23:54 作者: 因無茶而冷淡 時間: 2025-3-24 02:55 作者: 極小量 時間: 2025-3-24 09:10
Immunotherapy,eckpoint inhibitors (ICIs) have been approved by the US FDA, adding more options for RCC therapies. Recent clinical trials have shown the potency of ICIs, including anti-PD-1 and anti-CTLA-4 antibodies, as combination and monotherapy in both metastatic and local RCC. However, there is a continued ne作者: lacrimal-gland 時間: 2025-3-24 10:47
Evolving Treatment in Non-muscle-Invasive Bladder Cancer,g many other aspects. Historically, NMIBC has been treated with surgical resection and intravesical BCG. More recently, many other forms of intravesical therapy including non-BCG immunotherapy, chemotherapy, gene therapy, viral therapy, and others, have been studied to treat patients with NMIBC. Pri作者: Tdd526 時間: 2025-3-24 17:08
Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer,sed chemotherapy prior to surgical resection to address occult disseminated disease reduces risk of recurrence and is the current standard of care for MIBC, supported by level I evidence. While adjuvant chemotherapy could theoretically offer similar benefit, postoperative cisplatin-based chemotherap作者: Monocle 時間: 2025-3-24 21:47
Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer,ble for consideration based on certain selection criteria. This chapter describes the clinical entity of MIBC, discusses the selection criteria utilized for evaluating candidacy for SBP, and addresses a multitude of bladder-sparing approaches that have been utilized both historically and in current 作者: 種類 時間: 2025-3-25 00:34
Treatment of Metastatic Bladder Cancer,ular biology and the tumor microenvironment of bladder cancer has unlocked new opportunities for treatment. Immune checkpoint blockade with programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibodies has demonstrated durable responses in a subset of patients in the first- and作者: hysterectomy 時間: 2025-3-25 04:25
Book 2022ngly integrates radiation therapy to primary cancers, nodal beds, and even metastatic sites. The culmination of these advances has been the creation of multidisciplinary teams that expertly provide comprehensive care to patients with urologic cancers. This book provides the framework to create such 作者: Anhydrous 時間: 2025-3-25 11:31
High-Risk Localized Prostate Cancer,egies including surgery, radiation, and systemic therapy to ensure the best care in a rapidly evolving field. In this chapter we will review treatment of high-risk localized prostate cancer emphasizing the major pieces of evidence which underlie high-risk prostate cancer management.作者: 狂熱語言 時間: 2025-3-25 15:18 作者: 獨輪車 時間: 2025-3-25 17:24 作者: 關(guān)心 時間: 2025-3-25 20:44
Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer,literature describing oncologic outcomes, discussion of quality of life considerations, and description of treatment planning techniques for high-quality radiotherapy (RT) delivery. Ongoing randomized clinical trials (RCTs) of interest will be underscored throughout as they pertain to each aspect of treatment.作者: photophobia 時間: 2025-3-26 01:38
Creating a Multidisciplinary Clinic,ng this care model can be challenging as it requires significant administrative support and a substantial commitment from the participating physicians. This chapter is a guide for those starting a MDC of their own.作者: 樹木心 時間: 2025-3-26 04:18 作者: 搖曳的微光 時間: 2025-3-26 11:35
Immunotherapy for Metastatic Prostate Cancer,xicity remains an important consideration for all the work conducted so far. As more work is done to optimize immunotherapy in prostate cancer, future studies may need to extend their scope to immune cells outside of the T cell and perhaps beyond checkpoint inhibition.作者: Expressly 時間: 2025-3-26 12:44 作者: Cytokines 時間: 2025-3-26 17:46 作者: expound 時間: 2025-3-26 22:07
Kelly L. Stratton,Alicia K. MorgansIlluminates the benefits of multidisciplinary co-management.Emphasizes the upcoming expansion of new therapeutics for urologic malignancies.Written by leading experts in the practice of team-based uro作者: 按時間順序 時間: 2025-3-27 02:35 作者: 抵制 時間: 2025-3-27 06:21 作者: 思想 時間: 2025-3-27 10:51
https://doi.org/10.1007/978-3-030-89891-5genitourinary malignancy; team-based care; prostate cancer; bladder cancer; kidney cancer作者: Between 時間: 2025-3-27 14:32 作者: ethereal 時間: 2025-3-27 20:14
Ali Aria Razmaria,Heiko Schoder,Michael J. Morrisscher Metallk?rper“(2,3). F. Skaupy (4,5) pr?gte wegen der ?hnlichkeit der Methoden der Pulvermetallurgie mit denen der Keramik den Ausdruck ?Metallkeramik“, der neuerdings in Fachkreisen gegenüber dein umfassenderen Begriff ?Pulvermetallurgie“ mehr in den Hintergrund tritt (6).作者: GLADE 時間: 2025-3-28 00:54 作者: Flounder 時間: 2025-3-28 05:12
Hong Truong,Maria I. Carloes which see only a simple choice between retributivism and utilitarianism tend to obscure this variety and plurality. But even more seriously, the distinction between retributivism and utilitarianism is far from clear. That it reflects the traditional distinction between deontological and teleologi作者: 音樂學者 時間: 2025-3-28 09:43
Benjamin M. Eilender,Andrew B. Katims,John L. Pfail,John Sfakianos than punitive damages in Hungary. There has been only one detailed analysis published so far in Hungary but this study also follows an approach which is primarily a descriptive one. The absence of any contextual analysis in Hungary makes the analysis of punitive damages from a perspective of Hungarian private law even more complicated.作者: 疼死我了 時間: 2025-3-28 12:03 作者: Cholagogue 時間: 2025-3-28 18:09
Elizabeth Wulff-Burchfielduding mungbean, lentil, chickpea, lathyrus, pigeonpea, sweet potato, cassava and yam. Additionally, works on quinoa and Bambara groundnut are reviewed for the first time..978-3-642-07086-0978-3-540-34516-9作者: HIKE 時間: 2025-3-28 20:22 作者: 山間窄路 時間: 2025-3-29 01:12 作者: photopsia 時間: 2025-3-29 05:09 作者: senile-dementia 時間: 2025-3-29 09:27
Mohammad Atiq,Ravi Madanmpfen sowie in Flussigkeiten gel?sten Stoffen an Metallpulvern und den daraus hergestellten Sinterprodukten herangezogen werden [.]. Die Adsorption gestattet Aussagen uber Gro?e und Aktivitat der Oberflache.作者: resilience 時間: 2025-3-29 14:01 作者: 古文字學 時間: 2025-3-29 17:53 作者: refine 時間: 2025-3-29 21:08 作者: agonist 時間: 2025-3-30 02:57 作者: Pericarditis 時間: 2025-3-30 04:51
Supportive and Palliative Care for Genitourinary Malignancies,making and care and frailty for bladder cancer, as well as symptom management needs common to genitourinary malignancies including hematuria or voiding dysfunction. These as well as supportive care needs ubiquitous to advanced cancer such as pain, nausea, and mood disorders benefit from directed and作者: 細節(jié) 時間: 2025-3-30 12:05
Treatment of Metastatic Hormone-Sensitive Prostate Cancer,cetaxel, abiraterone acetate, enzalutamide, and apalutamide – have data demonstrating improved survival when used in addition to standard androgen deprivation therapy (ADT). No direct comparisons between these agents have been performed, and questions remain regarding optimal sequencing, although ov作者: 有權(quán)威 時間: 2025-3-30 12:29 作者: Flirtatious 時間: 2025-3-30 18:27 作者: Costume 時間: 2025-3-30 21:52
Radiotherapy for Advanced Prostate Cancer,he role of local therapy in patients with metastatic malignancies. As demonstrated in breast cancer, the benefit of local therapy is more pronounced in presence of effective systemic therapies [5]. Similar advancements have been noticed in prostate cancer. From the approval of docetaxel in the early作者: beta-carotene 時間: 2025-3-31 03:58 作者: 小爭吵 時間: 2025-3-31 06:52 作者: 高興一回 時間: 2025-3-31 11:14 作者: Jingoism 時間: 2025-3-31 13:47 作者: 魅力 時間: 2025-3-31 19:10
Treatment of Metastatic Bladder Cancer,inct therapeutic classes to further improve outcomes for patients with metastatic bladder cancer. This chapter focuses on the current therapeutic options for metastatic bladder cancer and gives a perspective on the future treatment of this disease.作者: chronology 時間: 2025-3-31 22:10
Book 2022ensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladdercancer, and immunotherapy approaches to advanced bladder and kidney cancer. The book also discusses the integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biops作者: 小隔間 時間: 2025-4-1 04:01
